GlassScriptPhysician profile
Thomas Martin Whelan
NPI 1972543692
$4,283.61
in general payments reported to CMS, 2019-2025
34 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.42 · 2020: $19.91 · 2021: $705 · 2022: $734 · 2023: $988 · 2024: $840 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,745 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,744.94 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $744.29 | 2021-2025 | Breztri, Farxiga |
| Abbvie INC. | $714.62 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $683.16 | 2021-2025 | |
| Glaxosmithkline, LLC. | $332.51 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.35 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $188.99 | 2021-2022 | |
| Eisai INC. | $132.67 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $128.47 | 2021-2022 | |
| Boston Scientific Corporation | $127.97 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $118.17 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Exact Sciences Corporation | $116.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $77.44 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $54.94 | 2021-2024 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $51.05 | 2022 | |
| Novo Nordisk INC | $48.11 | 2025 | Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $45.60 | 2022 | |
| Sanofi-Aventis U.S. LLC | $44.06 | 2021 | |
| Medtronic, INC. | $41.34 | 2022 | |
| Ironwood Pharmaceuticals, INC | $37.64 | 2023 | Linzess |
| Lilly USA, LLC | $31.33 | 2021 | |
| Upsher-Smith Laboratories LLC | $25.79 | 2022 | |
| Esperion Therapeutics, INC. | $25.14 | 2021 | |
| Krystal Biotech INC | $24.60 | 2023 | Vyjuvek |
| Shield Therapeutics INC | $24.56 | 2025 | |
| Seqirus USA INC | $23.59 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Janssen Biotech, INC. | $23.03 | 2025 | Tremfya |
| Organon LLC | $21.38 | 2022 | |
| Astellas Pharma US INC | $20.89 | 2019 | |
| Linus Health, INC. | $20.39 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.97 | 2024 | Voquezna |
| Philips North America LLC | $17.11 | 2023 | |
| Intra-Sana Laboratories | $15.77 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Vistapharm, INC. | $15.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Whelan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.